TCGA-37-3783-01A-01R-1201-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.540
- INTERFERON_ALPHA_RESPONSE+0.480
- TNFA_SIGNALING_VIA_NFKB+0.480
- INTERFERON_GAMMA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.450
- MYC_TARGETS_V1+0.450
- E2F_TARGETS+0.440
- INFLAMMATORY_RESPONSE+0.420
- MTORC1_SIGNALING+0.330
- IL6_JAK_STAT3_SIGNALING+0.310
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.470
- HEDGEHOG_SIGNALING-0.440
- MITOTIC_SPINDLE-0.420
- UV_RESPONSE_DN-0.310
- APICAL_JUNCTION-0.260
- MYOGENESIS-0.230
- NOTCH_SIGNALING-0.170
- TGF_BETA_SIGNALING-0.110
- HEME_METABOLISM-0.090
- PROTEIN_SECRETION-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.901 |
| 2 | DB8DD33B-34B6-4F4B-AD87-D666899A26BC | — | — | 0.896 |
| 3 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.893 |
| 4 | SRR8518165 | — | C | 0.890 |
| 5 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.882 |
| 6 | AE67DBFD-0DD0-4F86-A19F-D4789F585A2E | — | — | 0.879 |
| 7 | TCGA-35-4122-01A-01R-1107-07 | — | cohortA1 | 0.871 |
| 8 | SRR8518246 | — | C | 0.867 |
| 9 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.865 |
| 10 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.440 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.310 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |